Oct 25 2010
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu®. Sinovac filed the application with the Hong Kong Department of Health for the drug registration certificate for Anflu in November 2009. Obtaining the drug certificate in Hong Kong is a continuation of Sinovac's strategy to pursue opportunities to export its vaccines manufactured in mainland China to targeted areas and countries around the globe.
Dr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "We are advancing our international sales strategy by obtaining regulatory approvals in targeted areas and countries that will enable us generate sales by exporting our commercialized vaccines. We have successfully registered Anflu in Hong Kong and are actively evaluating marketing and distribution opportunities in this market."
SOURCE: Sinovac Biotech Ltd.